Finally, DESTINY-Lung03 part 4 is phase Ib study combining T-DXd plus rilvegostomig (anti-PD1 and anti -TIGIT bsAb) ± carboplatin as a first-line treatment for advanced HER2 OE NSCLC [120]. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.